Home » Newsletters » BioWorld Science

BioWorld Science

March 22, 2013

View Archived Issues

IRX-4204 shows efficacy in a number of preclinical and early clinical studies

Axon Neuroscience creates vaccine against modified tau protein

MHC class I-restricted vaccines prove clinically active against metastatic RCC

Ottawa Hospital Research Institute receives grant to investigate childhood brain cancer

Researchers present data from the ASCEND-HF trial

Tho1 protein as a new biomarker of early PSA recurrence in prostate cancer

The HER3 signaling pathway as a novel therapeutic target in MPNST

Scientists to develop gold-plated microchip to detect cancer growth

Promising antioxidant and Abeta properties demonstrated for YK-171

Prima BioMed earns grant to support development of CVac

Star Scientific reports preclinical anatabine data in ulcerative colitis

Cerecor obtains worldwide rights to Merck & Co.'s COMT inhibitors

DART Therapeutics obtains rights to SARM candidate for DMD

PARD-3 protein overexpression is associated with poor prognosis in ccRCC

Ipsen and Inspiration close sale of OBI-1 to Baxter International

New agents for hepatitis synthesized at Lupin

Novartis and IRM disclose novel PDGFR inhibitors

Wockhardt designs new series of antibacterial agents

Novartis synthesizes new product for COPD

Affinium Pharmaceuticals reports data from phase IIa trial of AFN-1252

New protein kinase inhibitors divulged by New Hope R&D Bioscience

Arbovax completes preclinical study of tetravalent dengue fever vaccine

Elafin granted second FDA orphan drug designation

Amorfix continues preclinical development of blood test for ALS

FDA committee recommends approval of Probuphine

Enrollment begins in FREEDOM phase III program for once- or twice-yearly diabetes therapy

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...